title: Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.
abstract: Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.
authors.affiliation: City of Hope National Medical Center, Duarte, California.
authors.forename: Monzr M
authors.initials: MM
authors.lastname: Al Malki
authors.affiliation: Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Mary
authors.initials: M
authors.lastname: Horowitz
authors.affiliation: Childrens University Hospital, Tuebingen, Germany.
authors.forename: Rupert
authors.initials: R
authors.lastname: Handgretinger
authors.affiliation: St. Jude Children's Research Hospital, Memphis, Tennessee.
authors.forename: Wing
authors.initials: W
authors.lastname: Leung
authors.affiliation: University of Montreal, Montreal, Canada.
authors.forename: Denis-Claude
authors.initials: DC
authors.lastname: Roy
authors.affiliation: Peking University Institute of Hematology, Beijing, China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
authors.forename: Ephraim
authors.initials: E
authors.lastname: Fuchs
authors.affiliation: Bambino Gesu Children's Hospital, Rome, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Locatelli
authors.affiliation: Institute Paoli Calmettes, Marseille, France.
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.affiliation: University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Shin
authors.initials: S
authors.lastname: Mineishi
authors.affiliation: Perugia University, Perugia, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Martelli
authors.affiliation: University of Minnesota, Minneapolis, Minnesota.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Miller
authors.affiliation: University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Carl
authors.initials: C
authors.lastname: June
authors.affiliation: Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
authors.forename: Hui-Sheng
authors.initials: HS
authors.lastname: Ai
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
authors.forename: Leo
authors.initials: L
authors.lastname: Luznik
authors.affiliation: Humanitas Clinical and Research Center, Milan, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Mavilio
authors.affiliation: Humanitas Clinical and Research Center, Milan, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Lugli
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Marcel R M
authors.initials: MRM
authors.lastname: van den Brink
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: sciurea@mdanderson.org.
authors.forename: Stefan O
authors.initials: SO
authors.lastname: Ciurea
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D019337:Hematologic Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D051379:Mice; D012008:Recurrence; D012495:San Francisco; D055502:Secondary Prevention; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000637:transplantation*; D014185:Transplantation, Isogeneic; D061349:Unrelated Donors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D006680:HLA Antigens; D003520:Cyclophosphamide
keywords: Cellular therapy; Haploidentical transplantation; Immunologic reconstitution after transplantation; Post-transplantation cyclophosphamide; T cell depleted